|(L-R): Alex Barkas, Managing Director, Prospect Venture Partners, Greg Wiederrecht, Ph.D., VP & Head, External Scientific Affairs Worldwide Licensing & External Research, Merck & Co., Inc., and Robert Blum, President and CEO, Cytokinetics Inc.
Steve Burrill, Chief Executive Officer, Burrill & Company
Alex Barkas, Managing Director, Prospect Venture Partners
Robert Blum, President and Chief Executive Officer, Cytokinetics Inc.
Frank Casty, Vice President, External Medical Relations, AstraZeneca
Greg Wiederrecht, Ph.D., Vice President & Head, External Scientific Affairs Worldwide Licensing & External Research, Merck & Co., Inc.
Robert J. Wills, Ph.D., Vice President, Alliance Management Pharmaceuticals Group, Johnson & Johnson
Shrinking pipelines and quickly expiring patents are only the beginning. The age of the blockbuster drug is on the wane, and the era of personalized medicine is approaching. How are the biotechnology and pharmaceutical industries adapting and innovating in this environment? Are new market dynamics paving the way to new collaborations with academia and philanthropy? Are new incentives or mechanisms needed to facilitate these collaborations?
Back to Program Schedule and Sessions